Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 841.20, up by 6.10 points or 0.73% from its previous closing of Rs. 835.10 on the BSE.

The scrip opened at Rs. 838.95 and has touched a high and low of Rs. 848.00 and Rs. 838.00 respectively. So far 31,000 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 965.15 on 20-Aug-2015 and a 52 week low of Rs. 706.40 on 24-Nov-2015.

Last one week high and low of the scrip stood at Rs. 848.00 and Rs. 791.00 respectively. The current market cap of the company is Rs. 2,02,619.00 crore.

The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 34.96% and 10.07% respectively.

Sun Pharmaceutical Industries’ subsidiary has received final approval from USFDA for its Abbreviated New Drug Application (ANDA) for generic version of Glumetza, Metformin Hydrochloride extended release tablets 500 mg and 1000 mg.

These Metformin Hydrochloride extended release tablets are therapeutic equivalents of Santarus Inc.’s Glumetza tablets. As per IMS MAT June 2016, these tablets have annual sales of approximately $1.2 billion in the US. The commercial launch of these tablets in the US is expected over the next few weeks.

Sun Pharma is the world's fifth largest specialty generic pharmaceutical company and India's top pharmaceutical company.